Fox Run Management L.L.C. Invests $645,000 in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Fox Run Management L.L.C. made a new investment in Vertex Pharmaceuticals by purchasing 1,330 shares valued at approximately $645,000.
• Institutional investors control 90.96% of Vertex Pharmaceuticals' stock, with several hedge funds significantly increasing their stakes recently.
• The consensus rating for Vertex Pharmaceuticals is a "Moderate Buy" with an average price target of $497.10, following various analyst ratings and target price revisions.

Fox Run Management L.L.C. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,330 shares of the pharmaceutical company's stock, valued at approximately $645,000.

Several other large investors have also bought and sold shares of VRTX. Vestmark Advisory Solutions Inc. grew its stake in shares of Vertex Pharmaceuticals by 113.8% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,388 shares of the pharmaceutical company's stock worth $6,006,000 after acquiring an additional 6,595 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Vertex Pharmaceuticals by 8.5% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 73,888 shares of the pharmaceutical company's stock worth $35,822,000 after purchasing an additional 5,800 shares during the last quarter. Holderness Investments Co. grew its position in Vertex Pharmaceuticals by 3.6% in the 1st quarter. Holderness Investments Co. now owns 1,364 shares of the pharmaceutical company's stock worth $661,000 after purchasing an additional 48 shares in the last quarter. E Fund Management Co. Ltd. increased its stake in Vertex Pharmaceuticals by 53.6% in the 1st quarter. E Fund Management Co. Ltd. now owns 9,884 shares of the pharmaceutical company's stock valued at $4,792,000 after buying an additional 3,448 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its stake in Vertex Pharmaceuticals by 1.6% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,205 shares of the pharmaceutical company's stock valued at $3,978,000 after buying an additional 131 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, August 5th. HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research report on Tuesday, August 5th. Canaccord Genuity Group reduced their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald decreased their target price on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Insider Buying and Selling

In related news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.9%

VRTX traded up $3.60 on Wednesday, hitting $394.36. The company's stock had a trading volume of 1,669,590 shares, compared to its average volume of 1,649,592. The company's 50 day simple moving average is $442.61 and its 200-day simple moving average is $463.11. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market cap of $101.11 billion, a P/E ratio of 28.19 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business's revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the company earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.